Document is current
Any future updates will be listed below
-
Authors
Bustamante Eduardo, Mariana
Popovici, Vlad
Imboden, Sara
Aebi, Stefan
Ballabio, Nadja
Altermatt, Hans Jörg
Günthert, Andreas
Jaggi, Rolf http://orcid.org/0000-0002-5975-9607
-
Funding
Funding for this research was provided by:
Berger-Janser Foundation
RECETOX Research Infrastructure (LM2015051 and CZ.02.1.01/0.0/0.0/16_013/0001761)
AstraZeneca Schweiz
Zonta Group Bern
Novartis
Pfizer
Bayer Pharma AG
- License Information
-
More Information
Article History
Received: 30 October 2018
Accepted: 27 May 2019
First Online: 7 June 2019
Ethics approval and consent to participate
: Clinical studies have to be presented to Cantonal Ethics Committees in Switzerland. Material that was used for this study was from patients and pathological samples that were collected in part before 1990 when informed consents were not commonly used. The Swiss law allows the use of such material under specific and very restrictive conditions. The Cantonal Ethics Committee of the Canton Bern examined the study and approved it on January, 18, 2018. The reference number is Ref 2017–02025.
: Not applicable.
: The authors declare that they have no competing interests.
